Vivet Therapeutics is committed to developing an innovative liver-directed gene therapy platform for the treatment of rare and severe inherited metabolic disorders. The company's development strategy is to target the liver with a novel synthetic adeno associated virus to introduce therapeutic genes to hepatocytes.
Vivet's focus is on developing innovative gene therapy technologies and treatments for Wilson disease, Progressive Familiar Intrahepatic Cholestasis, Cirtullinemia and other indications. Vivet's platform leverages new AAV-serotypes, advanced GMP manufacturing processes, disease models and innovative technologies to address current challenges in AAV-based gene therapy.
|Size (employees)||18 (est)|
Vivet Therapeutics total Funding
Vivet Therapeutics latest funding size
Time since last funding
|2 years ago|
Vivet Therapeutics investors
|Novartis Venture Fund, Roche Venture Fund, HealthCap, Columbus Venture Partners, Ysios Capital|
Vivet Therapeutics has 88 Twitter Followers. The number of followers has increased 0.6% month over month and increased 14.1% quarter over quarter
When was Vivet Therapeutics founded?
Vivet Therapeutics was founded in 2016.
How many employees does Vivet Therapeutics have?
Vivet Therapeutics has 18 employees.
Who are Vivet Therapeutics competitors?
Competitors of Vivet Therapeutics include Capstone Therapeutics, Arsanis and Perlara.
Where is Vivet Therapeutics headquarters?
Vivet Therapeutics headquarters is located at 29 Rue Tronchet, Paris.
Where are Vivet Therapeutics offices?
Vivet Therapeutics has an office in Paris.
How many offices does Vivet Therapeutics have?
Vivet Therapeutics has 1 office.